SAMHD1 Enhances Nucleoside-analogue Efficacy Against HIV-1 in Myeloid Cells

Overview

Journal Sci Rep

Specialty Science

Date 2017 Feb 22

PMID 28220857

Citations 18

Authors

Paula Ordonez

Simone Kunzelmann

Harriet C T Groom

Melvyn W Yap

Simon Weising

Chris Meier

Kate N Bishop

Ian A Taylor

Jonathan P Stoye

Affiliations

Soon will be listed here.

Abstract

SAMHD1 is an intracellular enzyme that specifically degrades deoxynucleoside triphosphates into component nucleoside and inorganic triphosphate. In myeloid-derived dendritic cells and macrophages as well as resting T-cells, SAMHD1 blocks HIV-1 infection through this dNTP triphosphohydrolase activity by reducing the cellular dNTP pool to a level that cannot support productive reverse transcription. We now show that, in addition to this direct effect on virus replication, manipulating cellular SAMHD1 activity can significantly enhance or decrease the anti-HIV-1 efficacy of nucleotide analogue reverse transcription inhibitors presumably as a result of modulating dNTP pools that compete for recruitment by viral polymerases. Further, a variety of other nucleotide-based analogues, not normally considered antiretrovirals, such as the anti-herpes drugs Aciclovir and Ganciclovir and the anti-cancer drug Clofarabine are now revealed as potent anti-HIV-1 agents, under conditions of low dNTPs. This in turn suggests novel uses for nucleotide analogues to inhibit HIV-1 in differentiated cells low in dNTPs.

Citing Articles

Platform-directed allostery and quaternary structure dynamics of SAMHD1 catalysis.

Acton O, Sheppard D, Kunzelmann S, Caswell S, Nans A, Burgess A Nat Commun. 2024; 15(1):3775.

PMID: 38710701 PMC: 11074143. DOI: 10.1038/s41467-024-48237-w.

Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnel.

Zhang S, Paulin C, Shu H, Yague-Capilla M, Michel M, Marttila P iScience. 2024; 27(2):108907.

PMID: 38318365 PMC: 10839966. DOI: 10.1016/j.isci.2024.108907.

Genome-wide screens connect HD82 loss-of-function to purine analog resistance in African trypanosomes.

Trenaman A, Tinti M, Atrih A, Horn D mSphere. 2023; 9(1):e0036323.

PMID: 38126788 PMC: 10826343. DOI: 10.1128/msphere.00363-23.

SAMHD1 as a prognostic and predictive biomarker in stage II colorectal cancer: A multicenter cohort study.

You D, Zhang S, Yan S, Ding Y, Li C, Cheng X Front Oncol. 2022; 12:939982.

PMID: 35978833 PMC: 9376296. DOI: 10.3389/fonc.2022.939982.

Targeting the DNA damage response and repair in cancer through nucleotide metabolism.

Helleday T, Rudd S Mol Oncol. 2022; 16(21):3792-3810.

PMID: 35583750 PMC: 9627788. DOI: 10.1002/1878-0261.13227.

References

ELION G . The biochemistry and mechanism of action of acyclovir. J Antimicrob Chemother. 1983; 12 Suppl B:9-17. DOI: 10.1093/jac/12.suppl_b.9. View

Yan J, Kaur S, DeLucia M, Hao C, Mehrens J, Wang C . Tetramerization of SAMHD1 is required for biological activity and inhibition of HIV infection. J Biol Chem. 2013; 288(15):10406-17. PMC: 3624423. DOI: 10.1074/jbc.M112.443796. View

Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K . Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 1980; 26(2):171-6. DOI: 10.1002/ijc.2910260208. View

Badia R, Pujantell M, Riveira-Munoz E, Puig T, Torres-Torronteras J, Marti R . The G1/S Specific Cyclin D2 Is a Regulator of HIV-1 Restriction in Non-proliferating Cells. PLoS Pathog. 2016; 12(8):e1005829. PMC: 4991798. DOI: 10.1371/journal.ppat.1005829. View

OBRIEN W, Namazi A, Kalhor H, Mao S, Zack J, Chen I . Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol. 1994; 68(2):1258-63. PMC: 236573. DOI: 10.1128/JVI.68.2.1258-1263.1994. View

Ahluwalia G, Cooney D, Mitsuya H, Fridland A, Flora K, Hao Z . Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol. 1987; 36(22):3797-800. DOI: 10.1016/0006-2952(87)90440-0. View

Witvrouw M, Pannecouque C, Switzer W, Folks T, De Clercq E, Heneine W . Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004; 9(1):57-65. View

Lingappa J, Baeten J, Wald A, Hughes J, Thomas K, Mujugira A . Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet. 2010; 375(9717):824-33. PMC: 2877592. DOI: 10.1016/S0140-6736(09)62038-9. View

McMahon M, Parsons T, Shen L, Siliciano J, Siliciano R . Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses. J Virol. 2011; 85(9):4618-22. PMC: 3126274. DOI: 10.1128/JVI.02423-10. View

10.

Amie S, Noble E, Kim B . Intracellular nucleotide levels and the control of retroviral infections. Virology. 2012; 436(2):247-54. PMC: 3804251. DOI: 10.1016/j.virol.2012.11.010. View

11.

Franzolin E, Pontarin G, Rampazzo C, Miazzi C, Ferraro P, Palumbo E . The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells. Proc Natl Acad Sci U S A. 2013; 110(35):14272-7. PMC: 3761606. DOI: 10.1073/pnas.1312033110. View

12.

White T, Brandariz-Nunez A, Valle-Casuso J, Amie S, Nguyen L, Kim B . The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe. 2013; 13(4):441-51. PMC: 3864637. DOI: 10.1016/j.chom.2013.03.005. View

13.

Baldauf H, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M . SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med. 2012; 18(11):1682-7. PMC: 3828732. DOI: 10.1038/nm.2964. View

14.

Mann D, OBrien S, Gilbert D, Reid Y, Popovic M, Gallo R . Origin of the HIV-susceptible human CD4+ cell line H9. AIDS Res Hum Retroviruses. 1989; 5(3):253-5. DOI: 10.1089/aid.1989.5.253. View

15.

Goldstone D, Ennis-Adeniran V, Hedden J, Groom H, Rice G, Christodoulou E . HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature. 2011; 480(7377):379-82. DOI: 10.1038/nature10623. View

16.

Kyei G, Cheng X, Ramani R, Ratner L . Cyclin L2 is a critical HIV dependency factor in macrophages that controls SAMHD1 abundance. Cell Host Microbe. 2014; 17(1):98-106. PMC: 4297224. DOI: 10.1016/j.chom.2014.11.009. View

17.

Gillis S, Watson J . Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. J Exp Med. 1980; 152(6):1709-19. PMC: 2186024. DOI: 10.1084/jem.152.6.1709. View

18.

De Clercq E . Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv Virus Res. 1993; 42:1-55. DOI: 10.1016/s0065-3527(08)60082-2. View

19.

Daluge S, Good S, Faletto M, Miller W, St Clair M, BOONE L . 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother. 1997; 41(5):1082-93. PMC: 163855. DOI: 10.1128/AAC.41.5.1082. View

20.

Faletto M, Miller W, Garvey E, St Clair M, Daluge S, Good S . Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother. 1997; 41(5):1099-107. PMC: 163857. DOI: 10.1128/AAC.41.5.1099. View